Compare PDYN & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDYN | CDXS |
|---|---|---|
| Founded | 1983 | 2002 |
| Country | United States | United States |
| Employees | 70 | N/A |
| Industry | Wholesale Distributors | Major Chemicals |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.0M | 256.3M |
| IPO Year | N/A | 2008 |
| Metric | PDYN | CDXS |
|---|---|---|
| Price | $7.13 | $2.59 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.67 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $138,590,000.00 |
| Revenue This Year | $384.48 | $7.73 |
| Revenue Next Year | $63.16 | $14.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $4.14 | $0.96 |
| 52 Week High | $12.79 | $3.87 |
| Indicator | PDYN | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 61.81 | 53.75 |
| Support Level | $6.70 | $2.40 |
| Resistance Level | $7.89 | $2.67 |
| Average True Range (ATR) | 0.46 | 0.20 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 81.42 | 37.30 |
Palladyne AI Corp is a software company focused on autonomy for robotic systems and solutions. Its artificial intelligence and machine learning software seeks to revolutionize the capabilities of robots, enabling them to observe, learn, reason, and act in structured and unstructured environments. AI and ML software platform of the company empowers robots to perceive variations or changes in the real-world environment, enabling them to autonomously maneuver and manipulate objects accurately in response. Palladyne AI software has wide application, including in industries such as automotive, aviation, construction, defense, general manufacturing, infrastructure inspection, logistics and warehousing.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.